Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 12/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 7/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 5/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2231876 | 0.81 | PDE4B (0.48) | PDE4BPDE3ACYP11B1CYP11B2CYP1A2 | |
| SCHEMBL2231099 | 0.81 | PDE4B (0.53) | PDE4BPDE3ACYP11B1CYP11B2 | |
| SCHEMBL2171784 | 0.78 | PDE4B (0.53) | PDE4BPDE3A | |
| SCHEMBL2232652 | 0.70 | CYP11B1 (0.39) | PDE4BPDE3ACYP11B1CYP11B2CYP1A2 | |
| SCHEMBL2170752 | 0.69 | PDE4B (0.52) | PDE4BPDE3A | |
| SCHEMBL3217750 | 0.67 | PDE4B (0.50) | PDE4BPDE3A | |
| SCHEMBL2959745 | 0.66 | PDE4B (0.52) | PDE4BPDE3A | |
| SCHEMBL7283560 | 0.65 | CYP11B2 (0.61) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2960864 | 0.65 | PDE4B (0.63) | PDE4BPDE3A | |
| SCHEMBL22826685 | 0.65 | TDO2 (0.42) | CYP11B1CYP11B2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
| EP-2351748-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | Kyorin Pharmaceutical Co., Ltd. (JP) | 2011-08-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224250-A1 | ISOQUINOLINE DERIVATIVE, AND PDE INHIBITOR COMPRISING SAME AS ACTIVE INGREDIENT | PDE5A, PDE2A, PDE3A | PDE4B 9/4885PDE3A 3/4885CYP11B1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.